At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Aug 10, 2026 at 16:01 ET
Alpha Tau Medical reported Q2 2026 financial results with a net loss of $68.8 million for the six months ended June 30, 2026, compared to $18.8 million in the same period of 2025, driven by higher R&D expenses and a $41.4 million financial expense from warrant remeasurement. The company highlighted multiple clinical milestones including 100% local disease control in glioblastoma, completion of enrollment in its pivotal cSCC trial, and a strategic collaboration with Tolmar for prostate cancer. Cash balance of $104.8 million provides runway for ongoing trials.
- Net loss for six months ended June 30, 2026 was $68.8 million ($0.76 per share) vs $18.8 million ($0.25 per share) in 2025
- Cash and equivalents, short-term deposits and restricted deposits of $104.8 million as of June 30, 2026
- Tolmar strategic collaboration includes $20M equity investment at 25% premium, $15M for manufacturing, and up to $161.5M in milestones
- REGAIN glioblastoma trial showed 100% local disease control and 67% complete response rate in first three patients
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access